Clinical assessment 2–4 months after pulmonary embolus
| BMI<30 kg·m−2 | BMI 30–39 kg·m−2 | BMI≥40 kg·m−2 | |
| Subjects n | 36 | 39 | 32 |
| Self-limiting activity | 15 (42) | 22 (56) | 22 (69) |
| NYHA functional class | 34 | 35 | 29 |
| I | 16 (47) | 18 (51) | 5 (17) |
| II | 16 (47) | 15 (43) | 19 (66) |
| III | 2 (6) | 2 (6) | 5 (17) |
| 6MWT m | 395 (308–496) | 408 (351–482) | 338 (219–407) |
| Decompensated heart failure# | 6 (17) | 13 (33) | 22 (69) |
| Iron deficiency¶ | 7 (19) | 10 (26) | 14 (44) |
| New OSA diagnosis at follow-up | 3 (8) | 12 (31) | 6 (19) |
| Sleep study recommended but not completed | 8 (22) | 9 (23) | 7 (22) |
| Echocardiogram | 35 | 39 | 32 |
| RV size | |||
| Normal | 23 (66) | 29 (74) | 14 (44) |
| Mild enlargement | 8 (23) | 7 (18) | 16 (50) |
| RV dysfunction | |||
| None | 24 (69) | 26 (67) | 23 (72) |
| Mild | 10 (29) | 13 (33) | 6 (19) |
| Residual unmatched perfusion defects+ | 18 (50) | 17 (44) | 15 (47) |
| Recurrent VTE§ | 1 (3) | 0 | 0 |
| Confirmed CTEPH | 5 (14) | 2 (5) | 2 (6) |
| Suspected CTEPH | 2 (5) | 4 (10) | 5 (16) |
| Total CTEPH | 7 (19) | 6 (15) | 7 (22) |
Data presented as mean (interquartile range) or n (%), unless otherwise indicated. BMI: body mass index; NYHA: New York Heart Association; 6MWT: 6-min walk test; OSA: obstructive sleep apnoea; RV: right ventricle; VTE: venous thromboembolism; CTEPH: chronic thromboembolic pulmonary hypertension. #: clinical diagnosis; ¶: criteria from Ferinject Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF) trial; +: 100 patients underwent V/Q testing (three patients in the heparin group and one embolectomy patient did not have testing); §: recurrent VTE occurred >1 year after the index event.